Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 9/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 7/20 | 1.00 |
| ▸ | MMP3 | P08254 | 3/20 | 1.00 |
| ▸ | MMP13 | P45452 | 3/20 | 1.00 |
| ▸ | GFER | P55789 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.85 |
| ▸ | POLB | P06746 | 3/20 | 0.85 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.79 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19736049 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1MMP3MMP13GFER | |
| SCHEMBL6887214 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1MMP3MMP13GFER | |
| SCHEMBL25992272 | 0.92 | AKR1B1 (0.85) | AKR1B1PTPN1MMP3MMP13GFER | |
| SCHEMBL29408626 | 0.92 | MEN1 (1.00) | AKR1B1PTPN1MMP3MMP13GFER | |
| SCHEMBL19736085 | 0.92 | MEN1 (1.00) | AKR1B1PTPN1MMP3MMP13GFER | |
| SCHEMBL12008737 | 0.90 | KMT2A (1.00) | AKR1B1PTPN1MMP3MMP13GFER | |
| SCHEMBL5219645 | 0.89 | PTPN1 (0.79) | AKR1B1PTPN1MMP3MMP13GFER | |
| SCHEMBL5214902 | 0.89 | PTPN1 (0.79) | AKR1B1PTPN1MMP3MMP13GFER | |
| SCHEMBL1060503 | 0.89 | AKR1B1 (1.00) | AKR1B1PTPN1MMP3MMP13GFER | |
| SCHEMBL17319262 | 0.89 | AKR1B1 (1.00) | AKR1B1PTPN1MMP3MMP13GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673816-B1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | Esswein, Angelika (DE) | 2004-01-06 | — | — | US | disclosed |
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | NR1H4, NR1D1, NR1I2 | AKR1B1 417/4885PTPN1 2479/4885MMP3 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.